BM212

Research use only, not for human use.

A novel antitubercular agent that possesses strong inhibitory activity against both Mycobacterium tuberculosis (MIC=0.7-1.5 ug/ml) and some nontuberculosis mycobacteria, inhibits transport activity of MmpL3.

A novel antitubercular agent that possesses strong inhibitory activity against both Mycobacterium tuberculosis (MIC=0.7-1.5 ug/ml) and some nontuberculosis mycobacteria, inhibits transport activity of MmpL3; also has marked activity against several species of yeasts, including Candida albicans and Cryptococcus neoformans, is also highly efficacious against mycobacteria which show resistance to the most common traditional drugs.

BM212 (2 μg/mL and 8 μg/mL) leads to major structural changes in the cell of M. abscessus CIP104536T S and R variants and results in the complete loss of the hydrophobic nanodomains observed on S cells but no significantly affect on R cells at dose of 2 μg/mL. BM212 (0.5-10 μg/mL, 7 days) inhibits the activity of Mycobacterium avium in U937 cells in a dose-dependent manner with a MIC of 0.5 μg/mL and 100% inhibition starting at a concentration of 1 μg/mL.

——

BM-212 | BM 212

GPCR/G Protein

Antibacterial

Antibacterial

Infection

——

146204-42-4

414.3707

C23H25Cl2N3

>98% (HPLC)

10 mM in DMSO

CN1CCN(CC2=C(C)N(C3=CC=C(Cl)C=C3)C(C4=CC=C(Cl)C=C4)=C2)CC1

Piperazine, 1-[[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl]-4-methyl-

(-20℃)

With Ice Pack

≥ 2 years